COMP <GO>
COLL vs UNH // RETURN ON INVESTED CAPITAL (ROIC)
Collegium Pharmaceutical Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: COLL 6
— UNH 5
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: COLL
LAST: $24.03 (+3.44%) • MKT CAP: $782.3M
roic
85.00%
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
roic
11.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COLL VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | COLL | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.30% | 88.57% | -29.27 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 85.00% | 11.47% | +73.53 | COLL | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.0x | 16.4x | -13.45 | COLL | /valuation <GO> |
| Free Cash Flow Yield | — | 6.48% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 23.00% | 4.82% | +18.18 | COLL | /operating-margins <GO> |
| Net Profit Margin | 8.10% | 3.14% | +4.96 | COLL | /net-margins <GO> |
| Revenue Growth (YoY) | 23.60% | 6.46% | +17.14 | COLL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.27 | 3.12 | -1.85 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.9 | 59.2 | -2.30 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.4x | 17.1x | -6.69 | COLL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $782.3M | $368.83B | -$368.05B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | COLL REV | UNH REV | COLL GROSS % | UNH GROSS % | COLL FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $780.6M | $447.57B | 59.3% | 88.7% | $327.6M | $16.07B |
| FY 2024 | $631.4M | $400.28B | 59.8% | 88.3% | $203.3M | $20.70B |
| FY 2023 | $566.8M | $371.62B | — | 89.6% | $274.7M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COLL // BETA —
UNH // BETA 0.33